Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of TYRA is 49 and suggests 45% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell